Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) |
DMP1 protein (SJ-96-0010) |
| Description | The cyclin D-binding Myb-like protein DMP1 is a tumor suppressor. DMP1 binding to DNA activates transcription, which can be inhibited by direct binding of D-type cyclins. Similar to p19ARF, DMP1 inhibits cell cycle progression and DMP1 knockout mice develop cancers either spontaneously or more readily following exposure to chemical carcinogens or ionizing radiation. Like p19ARF, DMP1 and its analogs may serve as potential prodrugs for cancer therapy as well as be valid targets in anti-cancer drug screening assays. Additionally, DMP1 may be used to regulate transcription of recombinant genes in mammalian cells. |
| Keywords | Tumor suppressor, cancer therapy prodrug, basic research material for transcriptional activation, cancer drug screening target. |
| Granted Patents or Published Applications | US Patent Nos. 6,180,763; 6,303,772; 6,673,902 |
| Related Scientific References | Inoue K, et. al. “Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis” Genes Dev. 14:1797-1809 (2000). Hirai H and Sherr C.J. “Interaction of D-type cyclins with a novel myb-like transcription factor” Mol Cell Biol 16(11): 6457-6467 (1996). |
| Licensing Opportunities | We are currently seeking licensing opportunities in all fields for the development of this technology. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: June 2005
